{"id":"W3029699663","doi":"10.1200/jco.2020.38.15_suppl.5515","title":"Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Hazard ratio; Prostate cancer; Internal medicine; Placebo; Discontinuation; Urology; Oncology; Gynecology; Cancer; Confidence interval; Androgen receptor; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003536528,0.00145045,0.002168054,0.0004954221,0.0003635085,0.0008254089,0.0006482154,0.001078625,0.004166472],"category_scores_gemma":[0.001906432,0.0004157947,0.0021905,0.0003725498,0.0008617702,0.0006035952,0.0005646136,0.00182419,0.0006621419],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005238391,"about_ca_system_score_gemma":0.001609958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009797399,"about_ca_topic_score_gemma":0.003509047,"domain_scores_codex":[0.9989074,0.0007715965,0.00006107409,0.00009809515,0.00007713482,0.00008463543],"domain_scores_gemma":[0.9991967,0.0002173798,0.0002703631,0.00005533554,0.00006488107,0.000195271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9404168,0.003806747,0.00195551,0.005195376,0.003088579,0.0001119459,0.0001228628,0.00068973,0.004962744,0.0003857951,0.003537807,0.0357262],"study_design_scores_gemma":[0.9312447,0.05651617,0.004894897,0.0002435593,0.002420174,0.0001062121,0.00003210753,0.0002400689,0.001001404,0.0002070172,0.003071888,0.00002170893],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9244439,0.04013614,0.002285326,0.001506164,0.0007978169,0.01264455,0.00998592,0.0002278659,0.007972308],"genre_scores_gemma":[0.95366,0.01540048,0.005199975,0.001928862,0.000425871,0.01034405,0.007075966,0.00005338803,0.005911421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004166472,"threshold_uncertainty_score":0.01870316,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1835691572354111,"score_gpt":0.4844959808260795,"score_spread":0.3009268235906684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}